MHRA, UK: People with serious allergies must avoid Pfizer vaccine

UK warns people who with serious allergies with to avoid Pfizer-BioNTech Covid-19 vaccine after two people reported adverse effects on the first day of rollout.

Britain’s medicine regulator has advised that people with a history of significant allergic reactions do not get Pfizer-BioNTech’s Covid-19 vaccine after two people reported adverse effects on the first day of rollout.

Britain began mass vaccinating its population on Tuesday in a global drive that poses one of the biggest logistical challenges in peacetime history, starting with the elderly and frontline workers

National Health Service medical director Stephen Powis said the advice had been changed after two NHS workers reported anaphylactoid reactions associated with receiving the vaccine.

“As is common with new vaccines the MHRA (regulator) have advised on a precautionary basis that people with a significant history of allergic reactions do not receive this vaccination, after two people with a history of significant allergic reactions responded adversely yesterday,” Powis said.

“Both are recovering well.”

The MHRA said it would seek further information, and Pfizer and BioNTech said they were supporting the MHRA’s investigation.

“Last evening, we were looking at two case reports of allergic reactions. We know from the very extensive clinical trials that this wasn’t a feature,” MHRA Chief Executive June Raine told lawmakers.

Pfizer has said people with a history of severe adverse allergic reactions were excluded from their late stage trials.

The FDA released documents on Tuesday in preparation for an advisory committee meeting on Thursday, saying the Pfizer vaccine’s efficacy and safety data met its expectations for authorization.

That briefing document said 0.63% of people in the vaccine group and 0.51% in the placebo group reported possible allergic reactions in trials, which Peter Openshaw, Professor of Experimental Medicine at Imperial College London, said was a very small number.

“The fact that we know so soon about these two allergic reactions and that the regulator has acted on this to issue precautionary advice shows that this monitoring system is working well,” he said.

(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.)

Follow more stories on Facebook and Twitter